Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. (1-(1-(3-fluoro-2-(trifluoromethyl)isonicotinoyl)-4-piperidinyl)-3-(4-(1h-pyrrolo(2,3-d)pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-azetidinyl)acetonitrile
1. 1334298-90-6
2. Incb039110
3. Incb-039110
4. 2-(3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-1-(1-(3-fluoro-2-(trifluoromethyl)isonicotinoyl)piperidin-4-yl)azetidin-3-yl)acetonitrile
5. Incb39110
6. 19j3781lpm
7. 2-[1-[1-[3-fluoro-2-(trifluoromethyl)pyridine-4-carbonyl]piperidin-4-yl]-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile
8. 3-azetidineacetonitrile, 1-(1-((3-fluoro-2-(trifluoromethyl)-4-pyridinyl)carbonyl)-4-piperidinyl)-3-(4-(7h-pyrrolo(2,3-d)pyrimidin-4-yl)-1h-pyrazol-1-yl)-
9. 1-[1-[[3-fluoro-2-(trifluoromethyl)-4-pyridinyl]carbonyl]-4-piperidinyl]-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]-3-azetidineacetonitrile
10. Itacitinib [usan]
11. Unii-19j3781lpm
12. 2-(3-(4-(7h-pyrrolo(2,3-d)pyrimidin-4-yl)-1h-pyrazol-1-yl)-1-(1-(3-fluoro-2-(trifluoromethyl)isonicotinoyl)piperidin-4-yl)azetidin-3-yl)acetonitrile
13. Examlpe 294 [wo2011112662]
14. Itacitinib [inn]
15. Itacitinib (usan/inn)
16. Itacitinib [usan:inn]
17. Itacitinib [who-dd]
18. Itacitinib (incb39110)
19. Itacitinib(incb039110)
20. Itacitinib; Incb039110
21. Gtpl8364
22. Schembl2396080
23. Chembl3622820
24. C26h23f4n9o
25. Amy1814
26. Bdbm246868
27. Incb 39110
28. Incb-39110
29. Bcp13794
30. Ex-a1674
31. Nsc792849
32. Nsc796224
33. Nsc801001
34. S7812
35. Zinc118795962
36. At16231
37. Ccg-270017
38. Cs-5593
39. Db12154
40. Nsc-792849
41. Nsc-796224
42. Nsc-801001
43. Sb13363
44. {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]azetidin-3-yl}acetonitrile
45. 1651228-00-0
46. 2-(1-{1-[3-fluoro-2-(trifluoromethyl)pyridine-4-carbonyl]piperidin-4-yl}-3-(4-{7h-pyrrolo[2,3-d]pyrimidin-4-yl}-1h-pyrazol-1-yl)azetidin-3-yl)acetonitrile
47. Ac-29031
48. As-75259
49. Hy-16997
50. A14390
51. D10944
52. Us10053465, 7
53. A902364
54. Q27891174
55. Incb039110;incb-039110;incb 039110
56. Incb39110;incb-39110;incb 39110; Incb039110; Incb-039110; Incb 039110
57. (1-(1-(3-fluoro-2-(trifluoromethyl)pyridine- 4-carbonyl)piperidin-4-yl)-3-(4-(7h-pyrrolo(2,3-d)pyrimidin- 4-yl)-1h-pyrazol-1-yl)azetidin-3-yl)acetonitrile
58. {1-{1-[3-fluoro-2- (trifluoromethyl) Isonicotinoyl] Piperidin-4- Yl}-3-[4-(7h- Pyrrolo[2,3- D]pyrimidin-4-yl)- 1h-pyrazol-1- Yl]azetidin-3- Yl}acetonitrile
59. 1-[1-[[3-fluoro-2-(trifluoromethyl)-4-pyridinyl]carbonyl]-4-piperidinyl]-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]-3-azetidineacetonitrile;itacitinib
60. 2-(3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-1-(1-(3-fluoro-2-(trifluoromethyl)-isonicotinoyl)piperidin-4-yl)azetidin-3-yl)acetonitrile
| Molecular Weight | 553.5 g/mol |
|---|---|
| Molecular Formula | C26H23F4N9O |
| XLogP3 | 1.6 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 11 |
| Rotatable Bond Count | 5 |
| Exact Mass | 553.19616904 g/mol |
| Monoisotopic Mass | 553.19616904 g/mol |
| Topological Polar Surface Area | 120 Ų |
| Heavy Atom Count | 40 |
| Formal Charge | 0 |
| Complexity | 977 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Treatment of acute graft versus host disease
L - Antineoplastic and immunomodulating agents
L04 - Immunosuppressants
L04A - Immunosuppressants
L04AA - Selective immunosuppressants
L04AA46 - Itacitinib
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]INTERMEDIATES SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
ABOUT THIS PAGE
A Itacitinib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Itacitinib, including repackagers and relabelers. The FDA regulates Itacitinib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Itacitinib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Itacitinib supplier is an individual or a company that provides Itacitinib active pharmaceutical ingredient (API) or Itacitinib finished formulations upon request. The Itacitinib suppliers may include Itacitinib API manufacturers, exporters, distributors and traders.
Itacitinib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Itacitinib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Itacitinib GMP manufacturer or Itacitinib GMP API supplier for your needs.
A Itacitinib CoA (Certificate of Analysis) is a formal document that attests to Itacitinib's compliance with Itacitinib specifications and serves as a tool for batch-level quality control.
Itacitinib CoA mostly includes findings from lab analyses of a specific batch. For each Itacitinib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Itacitinib may be tested according to a variety of international standards, such as European Pharmacopoeia (Itacitinib EP), Itacitinib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Itacitinib USP).
LOOKING FOR A SUPPLIER?
